Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Curaleaf Holdings Inc T.CURA

Alternate Symbol(s):  CURLF

Curaleaf Holdings, Inc. is an international provider of consumer cannabis products. The Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide selection and accessibility across the medical and adult use markets. It operates in approximately 17 states and owns and operates 147 dispensaries and 21 cultivation sites with a focus on states, including Arizona, Florida, Illinois, Massachusetts, New Jersey, New York and Pennsylvania. It cultivates, processes, markets and/or dispenses a range of permitted cannabis products across its operating markets, including flower and pre-rolls, dry-herb vaporizer cartridges, concentrates for vaporizing such as pre-filled vaporizer cartridges and disposable vaporizer pens, concentrates for dabbing, such as mints, topical balms and lotions, tinctures, lozenges, capsules and edibles. Through Curaleaf International Holdings Limited, it has a supply and distribution network throughout the European market.


TSX:CURA - Post by User

Post by blackspade799on Sep 18, 2024 11:19am
37 Views
Post# 36229036

20M Germans Could Benefit From Medical Marijuana

20M Germans Could Benefit From Medical Marijuana

survey on cannabis consumption in Germany showing 94% of respondents use cannabis for at least one health reason. Stress relief was the most common reason (60%), followed by sleeping disorders (50.4%) and pain relief (35%).

"The responses illustrate the immense potential and room for growth of the country's rapidly expanding medical cannabis industry following the implementation of the Cannabis Act (CanG) on April 1, 2024, which rescheduled cannabis as a non-narcotic. data from our survey, more than 20 million people in Germany could benefit from access to medical cannabis therapy."

However, within the past yearonly 10% of the survey participants obtained cannabis exclusively from licensed pharmacies while 79.6% reported negative experiences with the unlicensed market or safety concerns about unregulated products.
 

"Medical cannabis is a long-term, safe form of treatment that helps alleviate numerous symptoms of health conditions, usually with comparatively mild or no side effects," Dr. Julian Wichmann, M.D., co-founder of Bloomwell Group and CEO of Bloomwell told Benzinga. "However, it is still a taboo topic for many doctors in Germany, and specialist knowledge and expertise are necessary for maximum therapeutic success."

Wichmann further suggested that the continued reluctance of most doctors to prescribe marijuana in combination with decades of stigma impact consumers to turn to the illicit market. He suggested more outreach and education for the general public.

https://www.msn.com/en-us/health/other/20m-germans-could-benefit-from-medical-marijuana-but-most-struggle-to-find-prescribing-doctors/ar-AA1qqqX1

<< Previous
Bullboard Posts
Next >>